Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


Appu Rathinavelu

Appu Rathinavelu

Executive Director
Rumbaugh-Goodwin Institute for Cancer Research


Dr. Rathinavelu received his Ph.D., M. Phil., M.S., and B.S. from the University of Madras in India and conducted his Post-Doctoral work at Purdue University. He joined NSU’s College of Pharmacy in 1992 and he is currently the Executive Director of the Rumbaugh Goodwin Institute for Cancer Research of NSU. Dr. Rathinavelu has been involved in cancer research for more than two decades with great interest and expertise in drug discovery, pharmacogenomics, signal transduction, gene expression and natural products research. Dr. Rathinavelu holds 5 new patents for the discovery of novel anti-angiogenic compounds that are nearing completion of pre-clinical testing. Dr. Rathinavelu serves on the Governmental Affairs Committee of Bio Florida and was a member of the Center of Excellence for Marine Biology and Biotechnology consortium that included scientists from NSU, Florida Atlantic University and Florida International University. Dr. Rathinavelu has published, co-authored, and reviewed research articles and textbooks extensively. Dr. Rathinavelu is the recipient of the ‘Fulbright Award for Excellence in Teaching and Research’ for the year 2015 from the Council of the International Exchange of Scholars of the United States of America (USA) and the ‘Distinguished Professor of the Year’ Award from 2016 from NSU

Research Interest

Drug Discovery, Drug screening, Pre-clinical testing, Natural Products research, Genomics and Biotechnology. Rathinavelu's work also includes identification of gene defects, studying the effect of tumor micro environment on gene expression pattern and cellular mechanisms that enhance angiogenesis, cancer metastasis and drug resistance.